Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Numerous biopharma and life sciences companies have sought to put their stocks up for sale, but this week, two companies opted to pull out their IPO due to concerns over market stability.
More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival.
Calithera Biosciences is expanding its oncology portfolio with the addition of two clinical-stage compounds from Takeda Pharmaceuticals.
Choosing to exercise its options with a group of research and development partners, the pharma giant will accelerate a promising new C.F. gene therapy.
Merck and Acceleron struck an $11.5 billion merger agreement, but before that, rare-disease focused Acceleron Pharma was wooed by multiple suitors, including pharma giant Bristol Myers Squibb.
It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.
Seattle-based Immusoft announced it had inked a research pact and license option deal with Takeda to create, develop, and market cell therapies in rare inherited metabolic diseases with CNS manifestations and complications.
Cue Health went public on September 24 on the Nasdaq securities exchange under the ticker symbol HLTH.
GSK shares are climbing in premarket trading on rumors that the company’s consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.
Shares of Adamas Pharmaceuticals are up nearly 75% this morning after Supernus Pharmaceuticals announced it was acquiring the company and its Parkinson’s disease products.